Melatonin pharmacokinetics following two different oral surge-sustained release doses in older adults

Journal of Pineal Research

Volumn 52, Issue 4, 2012, Pages 437-445

  Gooneratne, Nalaka S ^a   Edwards, Alena Y Z ^b   Zhou, Chen ^a   Cuellar, Norma ^c   Grandner, Michael A ^a   Barrett, Jeffrey S ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c UNIVERSITY OF ALABAMA   (United States)

Author keywords

aged; insomnia; melatonin; pharmacokinetics; polysomnography

Indexed keywords

MELATONIN; PLACEBO;

AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG MEGADOSE; FEMALE; HORMONE BLOOD LEVEL; HUMAN; INSOMNIA; KIDNEY FUNCTION TEST; LIVER FUNCTION TEST; LOW DRUG DOSE; MALE; RANDOMIZED CONTROLLED TRIAL; SUSTAINED DRUG RELEASE;

AGE FACTORS; AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; ANALYSIS OF VARIANCE; AREA UNDER CURVE; ASPARTATE AMINOTRANSFERASES; CREATININE; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; KIDNEY; LIVER; MALE; MELATONIN; POLYSOMNOGRAPHY; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 84859733211     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/j.1600-079X.2011.00958.x     Document Type: Article

References (49)

1. Sanchez-Barcelo EJ, Mediavilla MD, Tan DX, et al., Clinical uses of melatonin: evaluation of human trials. Curr Med Chem 2010; 17: 2070-2095.
2. Slominski A, Tobin DJ, Zmijewski MA, et al., Melatonin in the skin: synthesis, metabolism and functions. Trends Endocrinol Metab 2008; 19: 17-24.
3. Burgess HJ, Revell VL, Molina TA, et al., Human phase response curves to three days of daily melatonin: 0.5 mg versus 3.0 mg. J Clin Endocrinol Metab 2010; 95: 1-7.
4. Galano A, Tan DX, Reiter RJ,. Melatonin as a natural ally against oxidative stress: a physicochemical examination. J Pineal Res 2011; 51: 1-16.
5. Mukherjee D, Roy SG, Bandyopadhyay A, et al., Melatonin protects against isoproterenol-induced myocardial injury in the rat: antioxidative mechanisms. J Pineal Res 2010; 48: 251-262.
6. Dauchy RT, Blask DE, Dauchy EM, et al., Antineoplastic effects of melatonin on a rare malignancy of mesenchymal origin: melatonin receptor-mediated inhibition of signal transduction, linoleic acid metabolism and growth in tissue-isolated human leiomyosarcoma xenografts. J Pineal Res 2009; 47: 32-42.
7. Otmani S, Demazieres A, Staner C, et al., Effects of prolonged-release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers. Hum Psychopharmacol 2008; 23: 693-705.
8. Wetterberg L, Bergiannaki JD, Paparrigopoulos T, et al., Normative melatonin excretion: a multinational study. Psychoneuroendocrinology 1999; 24: 209-226.
9. Ohayon MM, Carskadon MA, Guilleminault C, et al., Meta-analysis of quantitative sleep parameters from childhood to old age in healthy individuals: developing normative sleep values across the human lifespan. Sleep 2004; 27: 1255-1273.
10. Burgess HJ, Sletten T, Savic N, et al., Effects of bright light and melatonin on sleep propensity, temperature, and cardiac activity at night. J Appl Physiol 2001; 91: 1214-1222.
11. Olbrich D, Dittmar M,. Older poor-sleeping women display a smaller evening increase in melatonin secretion and lower values of melatonin and core body temperature than good sleepers. Chronobiol Int 2011; 28: 681-689.
12. Singer C, Tractenberg RE, Kaye J, et al., A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease. Sleep 2003; 26: 893-901.
13. Baskett JJ, Broad JB, Wood PC, et al., Does melatonin improve sleep in older people? A randomised crossover trial. Age Ageing 2003; 32: 164-170.
14. Luthringer R, Muzet M, Zisapel N, et al., The effect of prolonged-release melatonin on sleep measures and psychomotor performance in elderly patients with insomnia. Int Clin Psychopharmacol 2009; 24: 239-249.
15. Wade AG, Ford I, Crawford G, et al., Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety. BMC Med 2010; 8: 51.
16. Lee BJ, Parrott KA, Ayres JW, et al., Design and evaluation of an oral controlled release delivery system for melatonin in human subjects. Int J Pharm 1995; 124: 119-127.
17. Gehrman PR, Connor DJ, Martin JL, et al., Melatonin fails to improve sleep or agitation in double-blind randomized placebo-controlled trial of institutionalized patients with Alzheimer disease. Am J Geriatr Psychiatry 2009; 17: 166-169.
18. Lee BJ, Ryu SG, Cui JH,. Formulation and release characteristics of hydroxypropyl methylcellulose matrix tablet containing melatonin. Drug Dev Ind Pharm 1999; 25: 493-501.
19. Paul MA, Miller JC, Gray GW, et al., Melatonin treatment for eastward and westward travel preparation. Psychopharmacology (Berl) 2010; 208: 377-386.
20. Lane EA, Moss HB,. Pharmacokinetics of melatonin in man: first pass hepatic metabolism. J Clin Endocrinol Metab 1985; 61: 1214-1216.
21. Di W, Kadva A, Johnston A, et al., Variable bioavailability of oral melatonin (letter). N Engl J Med 1997; 336: 1028-1029.
22. Demuro RL, Nafziger AN, Blask DE, et al., The absolute bioavailability of oral melatonin. J Clin Pharmacol 2000; 40: 781-784.
23. Waldhauser F, Waldhauser M, Lieberman H, et al., Bioavailability of oral melatonin in humans. Neuroendocrinology 1984; 39: 307.
24. Fourtillan JB, Brisson AM, Gobin P, et al., Bioavailability of melatonin in humans after day-time administration of D(7) melatonin. Biopharm Drug Dispos 2000; 21: 15-22.
25. Brzezinski A,. Melatonin in humans. N Engl J Med 1997; 336: 186-195.
26. Kopin IJ, Pare CM, Axelrod J, et al., The fate of melatonin in animals. J Biol Chem 1961; 236: 3072-3075.
27. N ational A cademies-C ommittee on the F ramework for E valuating the S afety of D ietary S upplements. Prototype monograph on melatonin. In: Dietary Supplements: A Framework for Evaluation Safety, The National Academies Press, Washington, DC, 2004; pp. D1-D71.
28. Zhdanova IV, Wurtman RJ, Balcioglu A, et al., Endogenous melatonin levels and the fate of exogenous melatonin: age effects. J Gerontol A Biol Sci Med Sci 1998; 53: B293-B298.
29. Hughes RJ, Sack RL, Lewy AJ,. The role of melatonin and circadian phase in age-related sleep-maintenance insomnia: assessment in a clinical trial of melatonin replacement. Sleep 1998; 21: 52-68.
30. Maksoud A, Moore CA, Harshkowitz M,. The effect of melatonin administration on patients with sleep apnea. Sleep Res 1997; 26: 114.
31. Maestroni GJ, Cardinali DP, Esquifino AI, et al., Does melatonin play a disease-promoting role in rheumatoid arthritis? J Neuroimmunol 2005; 158: 106-111.
32. Conti A, Haran-Ghera N, Maestroni GJ,. Role of pineal melatonin and melatonin-induced-immuno-opioids in murine leukemogenesis. Med Oncol Tumor Pharmacother 1992; 9: 87-92.
33. Sutherland ER, Ellison MC, Kraft M, et al., Elevated serum melatonin is associated with the nocturnal worsening of asthma. J Allergy Clin Immunol 2003; 112: 513-517.
34. Buysse DJ, Ancoli-Israel S, Edinger JD, et al., Recommendations for a standard research assessment of insomnia. Sleep 2006; 29: 1155-1173.
35. Buysse DJ, Reynolds CF 3rd, Monk TH, et al., The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989; 28: 193-213.
36. Rechtschaffen A, Kales A,. A Manual of Standardization Terminology: Techniques and Scoring System for Sleep Stages of Human Subjects. Brain Information Services/Brain Research Institute, University of California at Los Angeles, Los Angeles, CA, 1968.
37. Riedel BW, Winfield CF, Lichstein KL,. First night effect and reverse first night effect in older adults with primary insomnia: does anxiety play a role? Sleep Med 2001; 2: 125-133.
38. Benloucif S, Burgess HJ, Klerman EB, et al., Measuring melatonin in humans. J Clin Sleep Med 2008; 4: 66-69.
39. Ursing C, Von Bahr C, Brismar K, et al., Influence of cigarette smoking on melatonin levels in man. Eur J Clin Pharmacol 2005; 61: 197-201.
40. Wright KJ, Badia P, Myers B, et al., Caffeine and light effects on nighttime melatonin and temperature levels in sleep-deprived humans. Brain Res 1997; 747: 78-84.
41. IBL I nternational GMBH. Melatonin Direct RIA (Serum/Plasma) RE29301. Hamburg, Germany, 2010.
42. Shah J, Langmuir V, Gupta SK,. Feasibility and functionality of OROS melatonin in healthy subjects. J Clin Pharmacol 1999; 39: 606-612.
43. Markantonis SL, Tsakalozou E, Paraskeva A, et al., Melatonin pharmacokinetics in premenopausal and postmenopausal healthy female volunteers. J Clin Pharmacol 2008; 48: 240-245.
44. Mistraletti G, Sabbatini G, Taverna M, et al., Pharmacokinetics of orally administered melatonin in critically ill patients. J Pineal Res 2010; 48: 142-147.
45. Zhdanova IV,. Melatonin as a hypnotic: pro. Sleep Med Rev 2005; 9: 51-65.
46. Riemersma-Van Der Lek RF, Swaab DF, Twisk J, et al., Effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities: a randomized controlled trial. JAMA 2008; 299: 2642-2655.
47. Lewy AJ, Emens JS, Lefler BJ, et al., Melatonin entrains free-running blind people according to a physiological dose-response curve. Chronobiol Int 2005; 22: 1093-1106.
48. E uropean M edicines A gency. Assessment Report for Circadin: Procedure No. EMEA/H/C/695. European Medicine Agency, London, UK, 2007, 52 pp.
49. Hahm H, Kujawa J, Augsburger L,. J Am Pharm Assoc (Wash) 1999; 39: 27-31.